NFE2L2 and cancer: The Keap1/Nrf2–ARE pathway involved in oxidative stress and inflammation is a new potential pharmacological target for the treatment of many diseases, including cancer, neurodegenerative diseases, diabetes, airway disorders, cardiovascular disease, inflammatory bowel diseases, rheumatoid arthritis and osteoarthritis [14,19].